BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fonseca DA, Amaral I, Pinto AC, Cotrim MD. Orphan drugs: major development challenges at the clinical stage. Drug Discov Today 2019;24:867-72. [PMID: 30658132 DOI: 10.1016/j.drudis.2019.01.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Lee JH. Pricing and Reimbursement Pathways of New Orphan Drugs in South Korea: A Longitudinal Comparison. Healthcare (Basel) 2021;9:296. [PMID: 33800373 DOI: 10.3390/healthcare9030296] [Reference Citation Analysis]
2 Matza LS, Phillips GA, Howell TA, Ciffone N, Ahmad Z. Estimating health state utilities associated with a rare disease: familial chylomicronemia syndrome (FCS). J Med Econ 2020;23:978-84. [PMID: 32479143 DOI: 10.1080/13696998.2020.1776719] [Reference Citation Analysis]
3 Prodinger C, Diem A, Ude-Schoder K, Piñón-Hofbauer J, Kitzmueller S, Bauer JW, Laimer M. Profiling trial burden and patients' attitudes to improve clinical research in epidermolysis bullosa. Orphanet J Rare Dis 2020;15:182. [PMID: 32650809 DOI: 10.1186/s13023-020-01443-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
4 Reuter K, Zhu Y, Angyan P, Le N, Merchant AA, Zimmer M. Public Concern About Monitoring Twitter Users and Their Conversations to Recruit for Clinical Trials: Survey Study. J Med Internet Res 2019;21:e15455. [PMID: 31670698 DOI: 10.2196/15455] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
5 Balijepalli C, Gullapalli L, Druyts E, Yan K, Desai K, Barakat S, Locklin J. Can Standard Health Technology Assessment Approaches Help Guide the Price of Orphan Drugs in Canada? A Review of Submissions to the Canadian Agency for Drugs and Technologies in Health Common Drug Review. Clinicoecon Outcomes Res 2020;12:445-57. [PMID: 32922050 DOI: 10.2147/CEOR.S264589] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Servais L, Camino E, Clement A, McDonald CM, Lukawy J, Lowes LP, Eggenspieler D, Cerreta F, Strijbos P. First Regulatory Qualification of a Novel Digital Endpoint in Duchenne Muscular Dystrophy: A Multi-Stakeholder Perspective on the Impact for Patients and for Drug Development in Neuromuscular Diseases. Digit Biomark 2021;5:183-90. [PMID: 34723071 DOI: 10.1159/000517411] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Ten Ham RMT, Klungel OH, Leufkens HGM, Frederix GWJ. A Review of Methodological Considerations for Economic Evaluations of Gene Therapies and Their Application in Literature. Value Health 2020;23:1268-80. [PMID: 32940245 DOI: 10.1016/j.jval.2020.04.1833] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Jonker CJ, de Vries ST, van den Berg HM, McGettigan P, Hoes AW, Mol PGM. Capturing Data in Rare Disease Registries to Support Regulatory Decision Making: A Survey Study Among Industry and Other Stakeholders. Drug Saf 2021;44:853-61. [PMID: 34091881 DOI: 10.1007/s40264-021-01081-z] [Reference Citation Analysis]